Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21669234 | 0.93 | TRPM8 (0.48) | TRPM8ATMCTSDSPPL2ACTRB1 | |
| SCHEMBL21669248 | 0.92 | TRPM8 (0.45) | TRPM8ATMCTSDSPPL2ACTRB1 | |
| SCHEMBL24283208 | 0.92 | TRPM8 (0.48) | TRPM8ATMCTSDSPPL2ACTRB1 | |
| SCHEMBL21669236 | 0.86 | CA1 (0.43) | ATMALDH1A1CTSLCTSS | |
| SCHEMBL21669328 | 0.84 | KMT2A (0.40) | CTSDALDH1A1 | |
| SCHEMBL21669303 | 0.84 | KLK5 (0.41) | ATMALDH1A1ITGB3ITGA2BREN | |
| SCHEMBL24282891 | 0.83 | TRPM8 (0.44) | TRPM8ATMCTSDSPPL2ACTRB1 | |
| SCHEMBL21669256 | 0.82 | CA1 (0.45) | ATMALDH1A1CTSLCTSS | |
| SCHEMBL24282890 | 0.82 | TRPM8 (0.46) | TRPM8ATMCTSDSPPL2ACTRB1 | |
| SCHEMBL24282829 | 0.80 | CA1 (0.43) | ATMALDH1A1CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829568-B1 | SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS | ALZHEON INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20220087967-A1 | SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2022-03-24 | — | — | US | disclosed |
| WO-2020028348-A1 | SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. (US) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087967-A1 | SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS | PSEN1, APP, PSEN2 | TRPM8 1633/4885ATM 3045/4885CTSD 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.